Terapia con adalimumab nei pazienti con malattia di Crohnsteroido-dipendente

E.Jan Irvine, Brian Feagan, James Rochon, André Archambault, Richard N Fedorak, Aubrey Groll, Douglas Kinnear, Fredric Saibil, John W.D McDonald, Quality of life: A valid and reliable measure of therapeutic efficacy in the treatment of inflammatory bowel disease Gastroenterology. ,vol. 106, pp. 287- 296 ,(1994) , 10.1016/0016-5085(94)90585-1

T. J. CREED, C. S. J. PROBERT, M. N. NORMAN, M. MOORGHEN, N. A. SHEPHERD, S. D. HEARING, C. M. DAYAN, , Basiliximab for the treatment of steroid-resistant ulcerative colitis: further experience in moderate and severe disease Alimentary Pharmacology & Therapeutics. ,vol. 23, pp. 1435- 1442 ,(2006) , 10.1111/J.1365-2036.2006.02904.X

Jean–Frédéric Colombel, William J. Sandborn, Paul Rutgeerts, Robert Enns, Stephen B. Hanauer, Remo Panaccione, Stefan Schreiber, Dan Byczkowski, Ju Li, Jeffrey D. Kent, Paul F. Pollack, Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial. Gastroenterology. ,vol. 132, pp. 52- 65 ,(2007) , 10.1053/J.GASTRO.2006.11.041

Gert Van Assche, Marc Van Ranst, Raf Sciot, Bénédicte Dubois, Séverine Vermeire, Maja Noman, Jannick Verbeeck, Karel Geboes, Wim Robberecht, Paul Rutgeerts, Progressive Multifocal Leukoencephalopathy after Natalizumab Therapy for Crohn's Disease The New England Journal of Medicine. ,vol. 353, pp. 362- 368 ,(2005) , 10.1056/NEJMOA051586

Matthew J Wyneski, Alex Green, Marsha Kay, Robert Wyllie, Lori Mahajan, Safety and efficacy of adalimumab in pediatric patients with Crohn disease. Journal of Pediatric Gastroenterology and Nutrition. ,vol. 47, pp. 19- 25 ,(2008) , 10.1097/MPG.0B013E318174E886

Chinyu Su, Gary R Lichtenstein, Treatment of inflammatory bowel disease with azathioprine and 6-mercaptopurine. Gastroenterology Clinics of North America. ,vol. 33, pp. 209- 234 ,(2004) , 10.1016/J.GTC.2004.02.004

Bruce E. Sands, Frank H. Anderson, Charles N. Bernstein, William Y. Chey, Brian G. Feagan, Richard N. Fedorak, Michael A. Kamm, Joshua R. Korzenik, Bret A. Lashner, Jane E. Onken, Daniel Rachmilewitz, Paul Rutgeerts, Gary Wild, Douglas C. Wolf, Paul A. Marsters, Suzanne B. Travers, Marion A. Blank, Sander J. van Deventer, Infliximab Maintenance Therapy for Fistulizing Crohn's Disease New England Journal of Medicine. ,vol. 350, pp. 876- 885 ,(2004) , 10.1056/NEJMOA030815

Matthieu Allez, L’immunisation contre l’infliximab, associée à des réactions d’intolérance et à une perte d’efficacité, peut être prévenue par l’utilisation d’immunosuppresseurs Gastroenterologie Clinique Et Biologique. ,vol. 28, pp. 701- 702 ,(2004) , 10.1016/S0399-8320(04)95055-5

Jeffrey Hyams, Wallace Crandall, Subra Kugathasan, Anne Griffiths, Allan Olson, Jewel Johanns, Grace Liu, Suzanne Travers, Robert Heuschkel, James Markowitz, Stanley Cohen, Harland Winter, Gigi Veereman–Wauters, George Ferry, Robert Baldassano, REACH Study Group, Induction and Maintenance Infliximab Therapy for the Treatment of Moderate-to-Severe Crohn’s Disease in Children Gastroenterology. ,vol. 132, pp. 863- 873 ,(2007) , 10.1053/J.GASTRO.2006.12.003

P. Lionetti, F. Bronzini, C. Salvestrini, C. Bascietto, R. Berni Canani, G. L. Dé Angelis, G. Guariso, S. Martelossi, B. Papadatou, A. Barabino, Response to infliximab is related to disease duration in paediatric Crohn's disease. Alimentary Pharmacology & Therapeutics. ,vol. 18, pp. 425- 431 ,(2003) , 10.1046/J.1365-2036.2003.01672.X